Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: GlobeNewswire
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference, Boston, MA. Fireside discussion, November 11, 2025, 3:30 p.m. ET. Stifel 2025 Healthcare Conference, New York, NY. Company presentation, November 12, 2025, 8:00 a.m. ET. Access to live webcasts of the events, as well as an archived recording, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website. About Zentalis PharmaceuticalsZentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN- c3), a potentially first-in-class and best-in-class WEE1 inhibitor for pati
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval [Seeking Alpha]Seeking Alpha
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZNTL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target lowered by analysts at Morgan Stanley from $8.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "market perform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
ZNTL
Earnings
- 11/10/25 - Beat
ZNTL
Sec Filings
- 11/12/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- ZNTL's page on the SEC website